Pidotimod

• Description:

  Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria, et al[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Pidotimod.html

• Concentration:

  10mM

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(C([C@H](CC2)NC2=O)=O)CSC1)O

• Molecular Formula:

  C9H12N2O4S

• Molecular Weight:

  244.27

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India|[2]Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17 (10) :803-818.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [121808-62-6]